FDA notifications.  FDA draft guidance on Hepatitis C/HIV coinfection.
D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy*; D006526:Hepatitis C / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D014481:United States; D014486:United States Food and Drug Administration
D019380:Anti-HIV Agents; D000998:Antiviral Agents